CANCER DISCOVERY

CONTENTS

JUNE 2011 ■ VOLUME 1 ■ NUMBER 1







RESEARCH ARTICLES

ON THE COVER A structural model shows dasatinib bound to the discoidin domain receptor 2 (DDR2) kinase. Hammerman and colleagues identified DDR2 as a potential therapeutic target in a subset of lung squamous cell carcinomas (SCC). They also found that dasatinib inhibited DDR2, and they observed a clinical response in one patient. These findings warrant further clinical evaluation of this drug and target in a subset of SCC patients. For details, please see the article by Hammerman and colleagues on page 78.

AACR American Association for Cancer Research

CANCER DISCOVERY

1 (1)

Cancer Discov 2011;1:OF4-89.